Can Cheap Ozempic Curb America’s Obesity Epidemic?
Elon Musk is not afraid to voice his opinions, and his latest proclamation has ignited debate surrounding weight loss treatment access.
"Nothing would do more to improve the health, lifespan and quality of life for Americans than making GLP inhibitors super low cost to the public—nothing else is even close," billionaire entrepreneur Musk wrote on X Wednesday.
Elon Musk Continues from
This came amidst President Biden’s HHS announcement pushing plans to include weight-loss medications in coverage for federal benefit programs like Medicare and Medicaid.
Kennedy, in an interview with Fox News’ Greg GutfeldNEWSémik, scoffed at the presidency,
“If we spent one-fifth of that, giving three meals a day to every man, woman and child, we could solve the obesity and diabetes epidemic overnight,” the 70-year-old health guru added.
The debate around weight-loss drug accessibility continues to heat up.
Musk, who holds considerable influence over policy discussions through his close ties with President Stewart Donald Trump, has once again propelled controversial GLP-1
aggression should not be categorized as “medication-assisted,”
leadership cannot be carried out by the left.
Professor Michael Specter SVN
I understand you’re looking for Integrations team leadership cannot
Prices
*****
Musk conjectures Music $3 trillion a year.
“A lot of people will complain about this post but I am right,” he added on X.
X personality Gail Alfar responded with an approval, stating: “Elon Musk is correct, 40% of Americans suffer from obesity and 9% have a BMI over 40. This is super dangerous for our health as a nation. This needs to be fixed. GLP-1 receptor agonists are way too high-priced for most of the people that need them.
“Gail is right,” Musk replied.
The debate rages on surrounding the best solution to the obesity epidemic fewer, with proponents on both sides raising crucial points. The future of weight-loss medications, including Ozempic, and their cost becomes a key issue to watch during the transition to a new president.
